{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "389", "lead_paragraph": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "pub_date": "2015-11-20T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Allergan Inc", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Federal Taxes (US)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Read, Ian C", "name": "persons"}], "blog": [], "_id": "564e1f2338f0d84d3be11021", "source": "The New York Times"}